MedPath

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk

Not Applicable
Completed
Conditions
Symptomatic Severe Aortic Stenosis
Registration Number
NCT01314313
Lead Sponsor
Edwards Lifesciences
Brief Summary

The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN XT transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic stenosis.

Detailed Description

The PIIA cohort is a prospective multi-center trial undergoing aortic valve replacement for severe aortic stenosis. Patients randomized to the treatment arm will receive an Edwards SAPIEN XT THV with either transfemoral, transapical or transaortic delivery access. Patients in the control arm will receive a surgical bioprosthetic heart valve via aortic valve replacement surgery.

To assure that patients with an STS score ≥ 4% have been selected.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2032
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
All-cause Death or Disabling Stroke to Two Years2 Years

All-cause Death or Disabling Stroke (Edwards SAPIEN XT THV vs SAVR)

Secondary Outcome Measures
NameTimeMethod
Adjusted Days Alive and Out of Hospital (DAOH) to Two Years2 years

The number of days the patients are alive and out of the hospital.

6MWT Change From BaselineBaseline and 2 years

Six Minute Walk Test change from baseline to 2 years

Effective Orifice Area (EOA)2 years
Total Aortic Regurgitation (AR) at 2 Years2 years

Total aortic regurgitation was assessed by the core lab as "Grade 0" = None, "Grade 1+" = Trace, "Grade 2+" = Mild, "Grade 3+" = Moderate and "Grade 4+" = Severe. Total regurgitation at two year was analyzed in the valve implant population.

NYHA Classification at 2 Years2 years

New York Heart Association (NYHA), functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest as no limitations and the highest unable to carry on any physical activity without discomfort.

Trial Locations

Locations (57)

Arkansas Heart Hospital/Clinic

🇺🇸

Little Rock, Arkansas, United States

Scripps Green Hospital

🇺🇸

La Jolla, California, United States

Scripps Memorial Hospital

🇺🇸

La Jolla, California, United States

Cedars-Sinai Medical Center

🇺🇸

Los Angeles, California, United States

Mercy General Hospital

🇺🇸

Sacramento, California, United States

UC Davis Medical Center

🇺🇸

Sacramento, California, United States

Stanford University Medical Center

🇺🇸

Stanford, California, United States

University of Colorado Hospital

🇺🇸

Denver, Colorado, United States

Washington Hospital Center

🇺🇸

Washington, District of Columbia, United States

Morton Plant Hospital

🇺🇸

Clearwater, Florida, United States

Scroll for more (47 remaining)
Arkansas Heart Hospital/Clinic
🇺🇸Little Rock, Arkansas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.